Trials / Completed
CompletedNCT00101426
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranirestat, (AS-3201) |
Timeline
- Start date
- 2004-10-01
- Completion
- 2006-09-01
- First posted
- 2005-01-11
- Last updated
- 2008-01-14
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00101426. Inclusion in this directory is not an endorsement.